What is it about?
The pharmacophoric features of the virtual cocrystallized protein of 178 Hsp90 proteins were obtained from the protein data bank and explored to generate 1260 pharmacophores evaluated using the decoy list composed of 1022 compounds. Accordingly, 51 pharmacophores were selected with high receiver operating characteristic (ROC) value for further processing. Subsequently, genetic algorithm and multiple linear regression analysis were employed to select an optimal combination of pharmacophoric models and 2D physicochemical descriptors capable of accessing a self-consistent quantitative structure-activity relationship (QSAR) of optimal predictive potential (R67(2) = 0.819, F = 43.0, R(2)LOO( )= 0.782, R(2)PRESS against 16 external test inhibitors equal 0.735). Two orthogonal pharmacophores emerged in the QSAR equation suggesting the existence of at least two binding modes accessible to ligands within the Hsp90 binding pocket. The fifth generated pharmacophoric model from Hsp90 protein 2XJX (2XJX_2_05), and the forth generated cocrystallized pharmacophoric model from Hsp90 protein 4LWF (4LWF_2_04) with area under the curve AUC-ROC values 0.812 and 0.876, respectively were selected to be used as a searching tool sequentially of the National Cancer Institute (NCI) database. The captured hits were mapped based on successful hypotheses and the best predicted hits were selected. Twenty-four hits showed Hsp90 inhibition, 15 hits were measured with low micromolar IC50 ranged from 5.0 μM to 77.1 μM.
Featured Image
Why is it important?
It is considered as a novel technique for discovery of new anticancer agents
Perspectives
Read the Original
This page is a summary of: Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation, Journal of Enzyme Inhibition and Medicinal Chemistry, August 2016, Taylor & Francis,
DOI: 10.1080/14756366.2016.1218485.
You can read the full text:
Contributors
The following have contributed to this page